PlainPharmaWatch

CMS Open Payments · Tool

Edge Endo LLC vs AstraZeneca UK Limited

Side-by-side comparison of CMS Open Payments data for Program Year 2024. Select different companies below to start a new comparison.

A larger reported total is not "better" or "worse", it is a neutral fact about disclosure volume; a reported payment documents a financial relationship, not evidence of wrongdoing.

Compare Different Companies

vs

Relationship comparison

Which recorded payment profile is more concentrated?

Edge Endo LLC has the more concentrated recorded General Payments recipient profile in Program Year 2024: its recipient-distribution HHI is 9,988, versus 5,304 for the other company. Its single largest recorded recipient represents 99.9% of that company's General Payments recipient total.

HHI summarizes how payments are distributed across recorded recipients: higher means a less evenly distributed recipient pattern. This is a description of CMS-reported General Payments only, not a finding about conduct, prescribing, quality, or wrongdoing. Read it with the recipient count and underlying records below.

Edge Endo LLC
HHI 9,988 · top recipient 99.9%
Ranked #132 of 1,838 companies by HHI
AstraZeneca UK Limited
HHI 5,304 · top recipient 72.7%
Ranked #314 of 1,838 companies by HHI

Payment Overview

Company A

Edge Endo LLC

Total Payments
$113.4M
% of Industry
0.8%
Transactions
41
Avg per Transaction
$2.8M
Recipients
40
Avg per Recipient
$2.8M
Payment Types
3
Top Payment Type
Acquisitions
Total Payments
$124.7M
% of Industry
0.9%
Transactions
4,340
Avg per Transaction
$28.7K
Recipients
2,367
Avg per Recipient
$52.7K
Payment Types
7
Top Payment Type
Royalty or License

Highlighted values indicate the higher figure for each metric.

Total payments compared

Edge Endo LLC vs AstraZeneca UK Limited - total reported payments in CMS Open Payments PY2024

AstraZeneca UK Limited$124.7MEdge Endo LLC$113.4M

General Payment Types Breakdown

Category shares use each company's General Payments total, not the all-tracks (General + Research + Ownership) hero figure.

Edge Endo LLC

Acquisitions $91.1M

99.9%

Consulting Fee $45.5K

0.0%

Long-Term Medical Supply or Device Loan $10.9K

0.0%

AstraZeneca UK Limited

Royalty or License $11.3M

73.2%

Consulting Fee $3.2M

20.7%

Travel and Lodging $422.7K

2.7%

Charitable Contribution $293.0K

1.9%

Compensation for Services Other Than Consulting $177.6K

1.2%

Food and Beverage $50.9K

0.3%

Top 5 General-Payment Recipients

This list uses CMS detailed General Payments records only; it excludes research and ownership/investment records, so it does not equal the all-category totals above. A reported payment documents a financial relationship, not evidence of wrongdoing; a higher total reflects reporting volume, not conduct. Verify directly at openpaymentsdata.cms.gov.

Edge Endo LLC

  1. 1

    CHARLES GOODIS

    $91,082,706.03 · 1 txns

  2. 2

    JUSTIN KOLNICK

    $28,550.87 · 19 txns

  3. 3

    CHARLES MAUPIN

    $11,042.88 · 13 txns

  4. 4

    GEORGE GOODIS

    $7,327.09 · 1 txns

  5. 5

    FREDERIC BARNETT

    $4,000.00 · 2 txns

AstraZeneca UK Limited

  1. 1

    Dana-farber Cancer Institute

    $11,211,159.75 · 4 txns

  2. 2

    David Linneus Horn

    $571,707.50 · 6 txns

  3. 3

    Univ Of Mi Hospitals & Hlth Ctrs

    $273,026.00 · 1 txns

  4. 4

    CHRISTOPHER B COOPER

    $101,693.30 · 22 txns

  5. 5

    JEFFREY Paul KANNE

    $87,250.00 · 9 txns

Summary Comparison

Metric Edge Endo LLC AstraZeneca UK Limited
Total Payments $113.4M $124.7M
% of Industry Total 0.8% 0.9%
Transaction Count 41 4,340
Avg per Transaction $2.8M $28.7K
Recipient Count 40 2,367
Avg per Recipient $2.8M $52.7K
Payment Type Count 3 7
Top Payment Type Acquisitions Royalty or License

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. All companies in the CMS Open Payments company corpus are available in the selector. Browse all companies →

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.